Stock Analysis on Net
Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Common-Size Income Statement
Quarterly Data

Edwards Lifesciences Corp., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Net sales 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of sales -23.28 -23.79 -24.30 -24.12 -24.86 -24.63 -25.75 -23.49 -24.38 -26.73 -27.97 -23.34 -24.01 -24.81 -26.09 -26.11 -26.48 -25.96 -25.08 -24.40
Gross profit 76.72% 76.21% 75.70% 75.88% 75.14% 75.37% 74.25% 76.51% 75.62% 73.27% 72.03% 76.66% 75.99% 75.19% 73.91% 73.89% 73.52% 74.04% 74.92% 75.60%
Selling, general, and administrative expenses -31.89 -27.81 -27.22 -27.19 -28.40 -26.93 -29.72 -27.27 -29.57 -27.99 -28.38 -28.23 -29.47 -29.73 -29.13 -28.61 -30.02 -29.77 -28.96 -25.99
Research and development expenses -17.51 -18.17 -16.37 -17.01 -16.42 -17.14 -19.69 -16.60 -16.51 -17.87 -17.66 -17.26 -16.68 -17.85 -16.33 -16.00 -16.50 -17.40 -15.97 -14.57
Intellectual property litigation income (expenses), net -0.53 -0.36 -0.17 -0.53 -0.39 -0.74 -41.07 -1.11 -1.18 -0.72 -0.64 -0.46 -19.93 -0.87 -0.58 -0.64 11.81 -1.67 -0.91 -1.15
Change in fair value of contingent consideration liabilities 1.36 -0.08 7.46 0.37 -0.44 0.79 -2.12 0.19 1.58 0.21 -0.74 -0.67 1.43 0.71 -1.16 -0.42 -0.29 2.03 -0.37 -0.12
Special charges 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.46 0.00 0.00 -2.42 -11.89 0.00 0.00 0.00 0.00 -1.18 0.00 0.00
Other operating expenses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.08 0.00
Operating income (loss) 28.16% 29.79% 39.40% 31.52% 29.49% 31.36% -18.35% 31.73% 26.47% 26.90% 24.61% 27.61% -0.54% 27.45% 26.71% 28.22% 38.51% 26.05% 28.63% 33.76%
Interest income (expense), net 0.04 -0.06 -0.07 0.02 0.04 0.07 0.19 0.40 0.37 0.26 0.22 0.20 0.18 -0.06 0.00 0.09 0.11 -0.01 -0.17 -0.27
Special gains (charges), net 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.79 -2.08 -0.06 -3.71 0.00
Other income (expense), net 0.11 0.11 0.32 0.45 0.35 0.50 -0.03 0.17 0.03 0.42 0.13 0.18 0.17 0.03 -0.12 0.35 -0.09 -0.19 -0.33 -0.26
Income (loss) before (provision for) benefit from income taxes 28.30% 29.84% 39.64% 32.00% 29.88% 31.93% -18.18% 32.29% 26.87% 27.58% 24.96% 28.00% -0.18% 27.43% 26.60% 29.45% 36.45% 25.78% 24.42% 33.23%
(Provision for) benefit from income taxes -3.08 -3.88 -4.07 -4.20 -3.91 -3.43 5.01 -4.78 -3.01 -2.47 -2.67 -2.85 0.90 -2.51 3.36 -6.36 -36.77 -5.08 -2.32 -7.18
Net income (loss) 25.22% 25.96% 35.57% 27.80% 25.97% 28.50% -13.18% 27.52% 23.87% 25.11% 22.29% 25.15% 0.72% 24.92% 29.96% 23.09% -0.32% 20.71% 22.11% 26.06%

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Edwards Lifesciences Corp. operating income (loss) as a percentage of net sales decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Income (loss) before (provision for) benefit from income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Edwards Lifesciences Corp. income (loss) before (provision for) benefit from income taxes as a percentage of net sales decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Edwards Lifesciences Corp. net income (loss) as a percentage of net sales decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.